AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 113 min read$VRTX

VRTX Looks 1.7% Undervalued on GF Value™ as JPMorgan Resumes Cov

JPMorgan resumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and raised its price target to $560. GF Value™ indicates VRTX is 1.7% undervalued at $514.56. The company has a GF Score™ of 87/100, reflecting strong fundamentals. Insider activity shows significant selling over the past year. The acquisition of Crinetics is expected to boost Vertex's endocrinology market presence and revenue.

Original reporting
gurufocus.com
Published Sep 11, 2026, 10:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VRTX
Bullish
medium confidence
Mentioned
$VRTX
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$VRTXBullishMed
01

Why it matters

The analyst upgrade provides a fresh catalyst that could drive short‑term buying pressure, but mixed insider activity tempers the signal.

02

Market read

Analyst coverage change is a primary driver for potential price movement in VRTX.

03

What to watch

Potential integration risks from the Crinetics acquisition and upcoming competition in the cystic fibrosis space.

Relevance 7/10Novelty 7/10Timing: Sep 11 2026 (same‑day release)

Background

Vertex Pharmaceuticals (NASDAQ: VRTX) is a large‑cap biotech with a diversified pipeline and recent acquisition of Crinetics.

Company-level read

Ticker impact

$VRTXBullishMedium confidence
Context

JPMorgan resumed coverage of Vertex Pharmaceuticals, upgraded to Overweight and raised the price target to $560 from $515.

Expected impact

Potential upside of 5‑10% if market digests the new target.

Evidence & confidence

The upgrade signals renewed confidence; however, insider selling and modest valuation discount temper the upside.

Market effects

Sector

Biotech sector may see a slight lift as a leading drugmaker receives analyst endorsement.

Regional

U.S. biotech equities could benefit from the positive coverage.

Global

Limited to investors tracking U.S. biotech and specialty pharma stocks.

Counterpoint

What could challenge this read

Insider selling and a modest 1.7% valuation discount suggest caution; the upgrade may be premature.

Key entities

  • analyst
    JPMorgan

    Resumed coverage, upgraded to Overweight, raised price target.

  • company
    Vertex Pharmaceuticals

    Biotech firm with recent Crinetics acquisition.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 11
$VRTXLow

VRTX Reinstated by JP Morgan -- Price Target Raised to $560

Vertex Pharmaceuticals (VRTX) was reinstated with an 'Overweight' rating by JP Morgan, which raised its price target to $560, up 8.74% from $515. The stock is currently trading at $514.56, slightly below its GF Value™ of $523.48, indicating a 1.7% undervaluation. Vertex has a strong GF Score™ of 87/100, with high ratings in financial strength and growth.

gurufocus.com2 min
SEP 11
$VRTXHigh

Vertex trades higher after JPM gives bullish rating

Vertex Pharmaceuticals (VRTX) stock rose 1.6% premarket after J.P. Morgan upgraded it to Overweight with a $560 price target, citing growth from its cystic fibrosis franchise and the recent Crinetics acquisition. The acquisition added Palsonify, a drug for acromegaly, and is expected to contribute to operating income by 2029. Morgan Stanley also recently recommended Overweight with a $665 target, highlighting diversification benefits.

tradingview.com1 min
SEP 10
$VRTXMed

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Myriad Genetics (MYGN) reported Q2 revenues of $190.7M, down 10.5% YoY, missing estimates. Its stock fell 40.7% to $3.19. Halozyme Therapeutics (HALO) reported $481M in revenues, up 47.7% YoY, beating estimates. Its stock rose 24.5% to $106.74. Amgen (AMGN) reported $10.05B in revenues, up 9.5% YoY, exceeding expectations. Its stock is flat at $391.29. The market has seen shifts in leadership due to AI and geopolitical concerns.

finance.yahoo.com3 min
SEP 8
$VRTXMed

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Goldman Sachs added Vertex Pharmaceuticals (VRTX) to its conviction list, setting a $653 price target. VRTX shares trade at $546, with targets ranging from $350 to $672. The company focuses on rare diseases, with strong revenue from cystic fibrosis treatments. Recent acquisitions and pipeline developments aim to diversify its portfolio, targeting over $5B in peak sales from new drugs.

yahoo.com4 min